EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Nonviral technologies can pave the way for CAR-NK cell therapy

Tobias Bexte, Lisa Marie Reindl, Evelyn Ullrich iD

Journal of Leukocyte Biology · 26.10.2023 · 114 (5) · 475-486

DOI: 10.1093/jleuko/qiad074 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Leukocyte Biology, online erschienen am 04.07.2023. Verfasst von Tobias Bexte und 2 weiteren Autor:innen. Beteiligte Einrichtung: Goethe University Frankfurt, Department of Pediatrics, Experimental Immunology & Cell Therapy, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 90 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Natural killer cells are a promising platform for cancer immunotherapy. Natural killer cells have high intrinsic killing capability, and the insertion of a chimeric antigen receptor can further enhance their antitumor potential. In first-in-human trials, chimeric antigen receptor–natural killer cells demonstrated strong clinical activity without therapy-induced side effects. The applicability of natural killer cells as an “off-the-shelf” product makes them highly attractive for gene-engineered cell therapies. Traditionally, viral transduction has been used for gene editing; however, the use of viral vectors remains a safety concern and is associated with high costs and regulatory requirements. Here, we review the current landscape of nonviral approaches for chimeric antigen receptor–natural killer cell generation. This includes transfection of vector particles and electroporation of mRNA and DNA vectors, resulting in transient modification and chimeric antigen receptor expression. In addition, using nonviral transposon technologies, natural killer cells can be stably modified ensuring long-lasting chimeric antigen receptor expression. Finally, we discuss CRISPR/Cas9 tools to edit key genes for natural killer cell functionality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenNeoplasmsHumansImmunotherapy, AdoptiveKiller Cells, NaturalImmunotherapyCell- and Tissue-Based Therapy

Stichwörter der Autor:innen

CARCRISPRelectroporationmRNAnatural killer cellnonviraltransposon

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Goethe University Frankfurt, Department of Pediatrics, Experimental Immunology & Cell Therapy, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany.
  • Frankfurt Cancer Institute, Goethe University, Paul-Ehrlich-Straße 42-44, 60596 Frankfurt am Main, Germany.
  • University Cancer Center (UCT), Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany.
  • Mildred Scheel Career Center (MSNZ), Hospital of the Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany.
  • German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ) partner site Frankfurt/Mainz; Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany.

ORCID-Profile: Evelyn Ullrich

Zitieren

APA

Bexte, T., Reindl, L. M., & Ullrich, E. (2023). Nonviral technologies can pave the way for CAR-NK cell therapy. Journal of Leukocyte Biology, 114(5), 475-486. https://doi.org/10.1093/jleuko/qiad074

Vancouver

Bexte T, Reindl LM, Ullrich E. Nonviral technologies can pave the way for CAR-NK cell therapy. Journal of Leukocyte Biology. 2023;114(5):475-486. doi:10.1093/jleuko/qiad074

BibTeX
@article{Bexte2023,
  author = {Bexte, Tobias and Reindl, Lisa Marie and Ullrich, Evelyn},
  title = {Nonviral technologies can pave the way for CAR-NK cell therapy},
  journal = {Journal of Leukocyte Biology},
  year = {2023},
  volume = {114},
  number = {5},
  pages = {475--486},
  doi = {10.1093/jleuko/qiad074}
}
Kostenlos starten →